News Feed Item

Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma Severities

For U.S. Media Only

RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat® inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in San Diego. Tiotropium is being studied to determine its efficacy and safety in treating asthma patients and is not currently approved for this indication.

The first results from the Phase 3 GraziaTinA-asthma® study (NCT01316380) were presented at the meeting, and showed that tiotropium delivered via the Respimat® inhaler improved lung function response, as measured by forced expiratory volume in one second (FEV1), in patients with mild asthma who remained symptomatic while receiving low-dose inhaled corticosteroid (ICS) treatment.

A pre-specified subset of data from the Phase 3 MezzoTinA-asthma® trials (NCT01172808/NCT01172821) presented at the meeting showed that, in patients with moderate asthma who remained symptomatic while receiving medium-dose ICS therapy, the addition of once-daily tiotropium reduced airflow obstruction independently of allergic status, as measured by the TH2 phenotype biomarkers.

Another subset of data presented at AAAAI found the addition of once-daily tiotropium in the Phase 3 PrimoTinA-asthma® trials (NCT00772538/NCT00776984) improved lung function responses independently of concomitant use of a leukotriene receptor antagonist (LTRA) in patients with severe asthma.

"Even with current treatment options, approximately 40 percent of patients with asthma remain symptomatic," said Pierluigi Paggiaro, MD, Professor of Respiratory Medicine, University of Pisa, and lead author on the GraziaTinA-asthma® presentation. "It is important to investigate the efficacy and safety of new treatment options across different severities."

GraziaTinA-Asthma® Data Presented at AAAAI

The GraziaTinA-asthma® trial is a Phase 3, randomized, double-blind, parallel-group trial designed to evaluate tiotropium delivered via the Respimat® inhaler as an add-on treatment in patients with persistent asthma who remain symptomatic while receiving at least low-dose maintenance ICS treatment (200-400 mcg budesonide equivalent). The primary endpoint was FEV1 peak(0-3h) response (change from baseline) at 12 weeks. The key secondary endpoint was trough FEV1. Additional secondary endpoints included FEV1 area under the curve (AUC(0-3h)), peak expiratory flow (PEF) responses (measured with the AM2+® device) and Asthma Control Questionnaire (ACQ-7) score. Of 464 treated patients, 155 received tiotropium 5 mcg, 154 received tiotropium 2.5 mcg, and 155 received placebo.

In the study, both tiotropium doses were statistically significant compared to placebo in FEV1 peak(0-3h) response and in trough FEV1 response at Week 12:

Peak FEV1(0-3h) Response

(adjusted mean difference)

Trough FEV1 Response

(adjusted mean difference)

5 mcg

128 mL (P = 0.0005)

122 mL (P = 0.001)

2.5 mcg

159 mL (P < 0.0001)

110 mL (P = 0.0028)

The FEV1 AUC(0-3h) response for patients receiving tiotropium was statistically significant versus placebo, as were the adjusted mean PEFAM and PEFPM responses versus placebo at Week 12:

FEV1 AUC(0-3h)


Adjusted Mean


Adjusted Mean


5 mcg

125 mL

(P = 0.0003)

25.6 L/min

(P < 0.0001)

27.6 L/min

(P < 0.0001)

2.5 mcg

149 mL

(P < 0.0001)

26.3 L/min

(P < 0.0001)

22.4 L/min

(P < 0.0001)

In the study, adjusted mean ACQ­-7 score, measured following treatment at 12 weeks, was similar across all treatment arms:

  • Tiotropium 5 mcg: 1.391
  • Tiotropium 2.5 mcg: 1.438
  • Placebo: 1.377

The incidence of reported adverse events (AEs) was similar across treatment groups: tiotropium 5 mcg, 32.3 percent; tiotropium 2.5 mcg, 31.2 percent; placebo, 29.0 percent.

"We are encouraged by these findings in mild asthma, as they build on previously presented positive results for tiotropium in moderate and severe asthma severities," said Tunde Otulana, MD, senior vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "The data from the UniTinA-asthma® clinical trial program presented at AAAAI add to our understanding of tiotropium's potential in asthma patients."

MezzoTinA-Asthma® Data Presented at AAAAI

Using the accepted serum IgE and eosinophil counts as biomarkers for TH2 inflammatory status, TH2-low and TH2-high subgroups were pre-defined in the MezzoTinA-asthma® trials at baseline as total serum IgE ≤ or >430 mcg/L, or blood eosinophils ≤ or >0.6×109/L. Of 2081 patients in the full analysis who received tiotropium or placebo, 1221/1961 were reported with IgE >430 mcg/L and 404/1969 with an eosinophil count of >0.6×109/L.

Both doses of tiotropium had a similar effect on peak and trough FEV1 versus placebo, independent of IgE and eosinophil count:

Adjusted Mean Peak FEV1(0-3h) Response


IgE ≤430 mcg/L


IgE >430 mcg/L






5 mcg

168 mL

193 mL

170 mL

240 mL

2.5 mcg

197 mL

237 mL

236 mL

176 mL

Trough FEV1 also improved with both doses of tiotropium versus placebo, independently of IgE and eosinophil count:

Adjusted Mean Trough FEV1 Response


IgE ≤430 mcg/L


IgE >430 mcg/L







5 mcg

139 mL

152 mL

137 mL

182 mL

2.5 mcg

167 mL

188 mL

185 mL

158 mL

In all subgroups, peak FEV1(0–3h) and trough FEV1 responses among patients who received tiotropium were within the same magnitude as responses in the active comparator salmeterol group.

The most frequently reported treatment-emergent AEs in both MezzoTinA-asthma® Phase 3 studies included asthma, PEF rate decrease and nasopharyngitis.

PrimoTinA-Asthma® Data Presented at AAAAI

Of the 912 patients in the PrimoTinA-asthma® trials randomized to receive either tiotropium (n=456) or placebo (n=456) for 48 weeks, 205 reported pre-screening LTRA use, 200 received LTRA at baseline, and 187 had efficacy data at Week 24. Use of LTRAs was permitted during run-in and treatment. Subgroups were defined by pre-screening LTRA use: "Yes"/"No". Mean percent predicted FEV1 at baseline was 55 percent in both groups.

Peak FEV1*

(adjusted mean difference

from placebo)

Trough FEV1**

(adjusted mean difference

from placebo)

LTRA "Yes"

103±51 mL (P = 0.0454)

96±48 mL (P = 0.0442)


111±28 mL (P < 0.0001)

91±25 mL (P = 0.0003)

*Peak FEV1 improvements independent of concomitant LTRA use [interaction P = 0.5747]

**Trough FEV1 improvements independent of concomitant LTRA use [interaction P = 0.4639]

The most frequently reported treatment-emergent AEs in both PrimoTinA-asthma® Phase 3 studies included asthma, PEF rate decrease and nasopharyngitis.

About the UniTinA-Asthma® Clinical Trial Program

The comprehensive Phase 3 trial program, UniTinA-asthma®, includes a number of clinical trials in adults, adolescents and pediatric patients across different asthma severities who remain symptomatic on current treatment with inhaled corticosteroid (ICS). The program includes over 4,000 patients in more than 150 sites globally. Results from the PrimoTinA-asthma® studies in severe asthma patients were presented at the 2012 European Respiratory Society (ERS) Annual Congress in Vienna, Austria, with additional sub-analyses presented at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, the 2013 American Thoracic Society (ATS) International Conference, the ERS Annual Congress 2013 and the American College of Chest Physicians (ACCP) Annual Meeting (CHEST 2013). Results from the MezzoTinA-asthma® studies in moderate asthma patients were presented at the ERS Annual Congress 2013.

About Asthma

Asthma is a chronic disease characterized by airway inflammation and bronchoconstriction. When a person with asthma comes into contact with an asthma trigger (e.g. infections, pollen, smoke), their airways can become inflamed, swollen and constricted and excess mucus is produced. These reactions can cause the airways to become narrower and irritated, making it difficult to breathe. People suffering from asthma experience recurrent episodes of wheezing, breathlessness, chest tightness and coughing. Asthma attacks occur when symptoms become more intense or frequent.

As of December 2012, an estimated 300 million people worldwide suffer from asthma. Estimates have shown that the number of people with asthma could grow by an additional 100 million people worldwide by 2025.

By avoiding asthma triggers, one can help to reduce the severity of asthma. Although asthma cannot be cured, appropriate management can control the disease in many patients. Despite current treatment options, approximately 40 percent of patients with asthma remain symptomatic.

Leading Respiratory Forward

Through research, treatments and patient-centric support services, the Boehringer Ingelheim (BI) lung health portfolio is designed to help address the challenges people living with a lung disease face every day. Leveraging the company's cutting edge science and leadership in chronic obstructive pulmonary disease (COPD), BI is researching new treatment approaches where needs persist. It is the company's goal to make a difference in the lives of patients with COPD, asthma, lung cancer, idiopathic pulmonary fibrosis and other respiratory diseases.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit www.us.boehringer-ingelheim.com

SOURCE Boehringer Ingelheim

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTrend processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
One of biggest questions about Big Data is “How do we harness all that information for business use quickly and effectively?” Geographic Information Systems (GIS) or spatial technology is about more than making maps, but adding critical context and meaning to data of all types, coming from all different channels – even sensors. In his session at @ThingsExpo, William (Bill) Meehan, director of utility solutions for Esri, will take a closer look at the current state of spatial technology and ar...
SYS-CON Events announced today that Interface Masters Technologies, a leader in Network Visibility and Uptime Solutions, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Interface Masters Technologies is a leading vendor in the network monitoring and high speed networking markets. Based in the heart of Silicon Valley, Interface Masters' expertise lies in Gigabit, 10 Gigabit and 40 Gigabit Eth...
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue an...
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and microservices. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your conta...
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his session at @DevOpsSummit 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will show how customers are able to achieve a level of transparency that enables everyon...
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
SYS-CON Events announced today that Streamlyzer will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Streamlyzer is a powerful analytics for video streaming service that enables video streaming providers to monitor and analyze QoE (Quality-of-Experience) from end-user devices in real time.
SYS-CON Media announced today that @WebRTCSummit Blog, the largest WebRTC resource in the world, has been launched. @WebRTCSummit Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. @WebRTCSummit Blog can be bookmarked ▸ Here @WebRTCSummit conference site can be bookmarked ▸ Here
In past @ThingsExpo presentations, Joseph di Paolantonio has explored how various Internet of Things (IoT) and data management and analytics (DMA) solution spaces will come together as sensor analytics ecosystems. This year, in his session at @ThingsExpo, Joseph di Paolantonio from DataArchon, will be adding the numerous Transportation areas, from autonomous vehicles to “Uber for containers.” While IoT data in any one area of Transportation will have a huge impact in that area, combining sensor...
DevOps theory promotes a culture of continuous improvement built on collaboration, empowerment, systems thinking, and feedback loops. But how do you collaborate effectively across the traditional silos? How can you make decisions without system-wide visibility? How can you see the whole system when it is spread across teams and locations? How do you close feedback loops across teams and activities delivering complex multi-tier, cloud, container, serverless, and/or API-based services?
Almost everyone sees the potential of Internet of Things but how can businesses truly unlock that potential. The key will be in the ability to discover business insight in the midst of an ocean of Big Data generated from billions of embedded devices via Systems of Discover. Businesses will also need to ensure that they can sustain that insight by leveraging the cloud for global reach, scale and elasticity.